Argenica Therapeutics Limited

ASX:AGN Stock Report

Market Cap: AU$92.9m

Argenica Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Liz Dallimore

Chief executive officer

AU$424.2k

Total compensation

CEO salary percentage67.8%
CEO tenure2.6yrs
CEO ownership1.3%
Management average tenureno data
Board average tenure1.6yrs

Recent management updates

Recent updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Sep 23
Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12
Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Jul 20
Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Apr 20
Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Nov 30
We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Aug 12
Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Apr 29
Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Sep 16
We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

CEO Compensation Analysis

How has Liz Dallimore's remuneration changed compared to Argenica Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$424kAU$288k

-AU$5m

Mar 31 2024n/an/a

-AU$5m

Dec 31 2023n/an/a

-AU$5m

Sep 30 2023n/an/a

-AU$5m

Jun 30 2023AU$675kAU$250k

-AU$5m

Mar 31 2023n/an/a

-AU$4m

Dec 31 2022n/an/a

-AU$4m

Sep 30 2022n/an/a

-AU$4m

Jun 30 2022AU$337kAU$228k

-AU$4m

Mar 31 2022n/an/a

-AU$3m

Dec 31 2021n/an/a

-AU$3m

Sep 30 2021n/an/a

-AU$2m

Jun 30 2021AU$145kAU$31k

-AU$1m

Compensation vs Market: Liz's total compensation ($USD276.54K) is about average for companies of similar size in the Australian market ($USD298.50K).

Compensation vs Earnings: Liz's compensation has been consistent with company performance over the past year.

CEO

Liz Dallimore

2.6yrs

Tenure

AU$424,246

Compensation

Dr. Liz Dallimore (B. Sc. (Hons), MBA, PhD, GAICD) serves as Chief Executive Officer of Argenica Therapeutics Limited ands serves as its Managing Director and Director since April 4, 2022. She is a researc...

Board Members

NamePositionTenureCompensationOwnership
Liz Dallimore
CEO, MD & Director2.6yrsAU$424.25k1.28%
A$ 1.2m
Dianne Angus
Independent Non-Executive Chairmanless than a yearAU$102.58kno data
Geoffrey Donnan
Member of Clinical Advisory Committeeno datano datano data
Terence Budge
Independent Non-Executive Director3.8yrsAU$44.40k0.63%
A$ 584.1k
Robert Black
Independent Non-Executive Directorless than a yearno data0.020%
A$ 18.1k
Paul Bailey
Member of Clinical Advisory Committeeno datano datano data
Tim Phillips
Member of Clinical Advisory Committeeno datano datano data
David Blacker
Chairman of Clinical Advisory Committeeno datano datano data
Jeffery Saver
Member of Clinical Advisory Committee2.3yrsno datano data
Mark Etherton
Independent Non-Executive Directorless than a yearno datano data

1.6yrs

Average Tenure

Experienced Board: AGN's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.